The World: New York - J&J calls review of $110m pharmaceuticals brief

Johnson & Johnson has begun a review of its US pharmaceuticals business, which has an estimated spend of $110 million.

Industry sources say the group is looking for a holding company to handle all marketing disciplines for its pharmaceuticals division.

Its brands include the pain reliever Ultram ER, the cancer and blood disease treatment Procrit and the migraine remedy Topamax.

Topamax will lose patent protection at the end of September when it will begin to face generic competition.

J&J said the review was "part of our ongoing efforts to ensure that we leverage the best creative talent in advertising and marketing".